Contents | 3 of 23

Incidence and clinical features of ethambutol-induced optic neuropathy in Korea.

Update Item Information
Title Journal of Neuro-Ophthalmology, December 2008, Volume 28, Issue 4
Date 2008-12
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah, 10 N 1900 E SLC, UT 84112-5890
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s6zk8ns8
Setname ehsl_novel_jno
ID 225814
Reference URL https://collections.lib.utah.edu/ark:/87278/s6zk8ns8

Page Metadata

Title Incidence and clinical features of ethambutol-induced optic neuropathy in Korea.
Creator Lee, Eun Ji; Kim, Seong-Joon; Choung, Ho Kyung; Kim, Jeong Hun; Yu, Young Suk
Affiliation Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.
Abstract BACKGROUND: The incidence, clinical manifestations, and contributory factors in ethambutol-induced optic neuropathy (EON) have not been widely studied. METHODS: A retrospective chart review of 857 patients who took ethambutol for treatment of tuberculosis identified 89 patients who complained of decreased vision after initiation of treatment and were therefore referred to the ophthalmology clinic of Seoul National University Hospital, Korea, between January 2003 and December 2005. Information was extracted in regard to systemic illnesses, duration and dose of ethambutol therapy, visual acuity, color vision, ophthalmoscopic examination, visual fields, and visual evoked potentials (VEPs). RESULTS: EON was diagnosed in 13 (1.5%) patients during a follow-up period of 12.54 +/- 9.97 months. The average dose of ethambutol was 17.85 +/- 2.21 mg/kg/day, and the duration of therapy was 9.38 +/- 10.12 months. Ophthalmic findings included decreased visual acuity (65.4%), abnormal visual fields (65.4%), abnormal color vision (61.5%), optic disc pallor (38.5%), or increased latency on VEP tests (65.4%). Slightly less than one third of patients showed improvement in visual function after discontinuing ethambutol. The latency for recovery was 5.38 +/- 1.71 months. No patient with optic disc pallor at the time of diagnosis of EON showed visual function improvement. Renal dysfunction and the daily dose of ethambutol, but not the duration of treatment, contributed to EON. CONCLUSIONS: Based on this study, the incidence of EON in Koreans is estimated to be <2%. However, visual function after discontinuation of ethambutol is reversible in only a minority of patients and does not occur if optic disc pallor is present. Renal dysfunction and daily dose of ethambutol, but not duration of ethambutol treatment, seem to be related to development of EON.
Subject Adult; Older people; Older people, 80 and over; Antitubercular Agents; Dose-Response Relationship,; Drug; Ethambutol; Female; Glomerular Filtration Rate; Humans; Incidence; Korea; Male; Metabolic Clearance Rate; Middle Older people; Neurologic Examination; Optic Disk; Optic Nerve; Optic Nerve Diseases; Recovery of Function; Retrospective Studies; Vision, Low
OCR Text Show
Format application/pdf
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah, 10 N 1900 E SLC, UT 84112-5890
Setname ehsl_novel_jno
ID 225792
Reference URL https://collections.lib.utah.edu/ark:/87278/s6zk8ns8/225792